Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review

doi:10.3390/toxins13060370

Review

. 2021 May 22;13(6):370.

doi: 10.3390/toxins13060370.

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review

Dirk Dressler¹, Lizhen Pan^{2

3}, Junhui Su^{2

3}, Fei Teng^{2

3}, Lingjing Jin^{2

4}

Affiliations

¹ Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl‑Neuberg‑Str. 1, 30625 Hannover, Germany.
² Neurotoxin research Center of Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China.
³ Department of Neurology, Shanghai Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China.
⁴ Department of Neurorehabilitation, Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji Univeirsity School of Medicine, No. 2209 Guangxing Rd, Shanghai 201619, China.

PMID: 34067301
PMCID: PMC8224638
DOI: 10.3390/toxins13060370

Review

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review

Dirk Dressler et al. Toxins (Basel). 2021.

. 2021 May 22;13(6):370.

doi: 10.3390/toxins13060370.

Authors

Dirk Dressler¹, Lizhen Pan^{2

3}, Junhui Su^{2

3}, Fei Teng^{2

3}, Lingjing Jin^{2

4}

Affiliations

¹ Movement Disorders Section, Department of Neurology, Hannover Medical School, Carl‑Neuberg‑Str. 1, 30625 Hannover, Germany.
² Neurotoxin research Center of Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration of Ministry of Education, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China.
³ Department of Neurology, Shanghai Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China.
⁴ Department of Neurorehabilitation, Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center), Tongji Univeirsity School of Medicine, No. 2209 Guangxing Rd, Shanghai 201619, China.

PMID: 34067301
PMCID: PMC8224638
DOI: 10.3390/toxins13060370

Abstract

In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli^®, Lantox^®, Prosigne^®, Lanzox^®, Redux^®, Liftox^®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN- onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN's registrations in Europe and North America.

Keywords: Chinese botulinum toxin; botulinum toxin; complete English bibliography; formalised review; lanbotulinumtoxinA; therapy.

PubMed Disclaimer

Conflict of interest statement

Dirk Dressler DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. He provides professional consulting services to pharmaceutical companies and professional investment institutions on all aspects of botulinum toxin drugs.

Cited by

Round-Sharp Needle for Limb Spasms After a Stroke: Study Protocol for a Randomized Controlled Trial.
Ye H, Liu J, Cheng H, He Y, Li C, Gao Y, Xu X. Ye H, et al. J Multidiscip Healthc. 2025 Jun 4;18:3179-3189. doi: 10.2147/JMDH.S512206. eCollection 2025. J Multidiscip Healthc. 2025. PMID: 40486254 Free PMC article.
Retroform Cervical Dystonia: Target Muscle Selection and Efficacy of Botulinum Toxin Injection.
Hu Y, Pan L, Su J, Chen S, Zhang X, Pan Y, Jin L, Teng F. Hu Y, et al. Front Neurol. 2022 Jul 26;13:952456. doi: 10.3389/fneur.2022.952456. eCollection 2022. Front Neurol. 2022. PMID: 35959387 Free PMC article.
Update on Non-Interchangeability of Botulinum Neurotoxin Products.
Brin MF, Nelson M, Ashourian N, Brideau-Andersen A, Maltman J. Brin MF, et al. Toxins (Basel). 2024 Jun 10;16(6):266. doi: 10.3390/toxins16060266. Toxins (Basel). 2024. PMID: 38922160 Free PMC article. Review.
Industrial Production and Therapeutic Application of Botulinum Neurotoxin: The Role of C. botulinum Type A.
Kadir SD. Kadir SD. Pharm Nanotechnol. 2024;12(2):99-107. doi: 10.2174/2211738511666230825150259. Pharm Nanotechnol. 2024. PMID: 37642004 Review.
Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity.
Martin MU, Frevert J, Tay CM. Martin MU, et al. Toxins (Basel). 2024 Feb 10;16(2):101. doi: 10.3390/toxins16020101. Toxins (Basel). 2024. PMID: 38393178 Free PMC article. Review.

See all "Cited by" articles

References

1. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus. 1980;17:21–25. doi: 10.3928/0191-3913-19800101-06. - DOI - PubMed
1. Dressler D. Botulinum toxin drugs: Brief history and outlook. J. Neural Transm. 2016;123:277–279. doi: 10.1007/s00702-015-1478-1. - DOI - PubMed
1. Barbosa P.M., Rodrigues G.R., de Oliveira D.S., de Souza C.P., Tumas V. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia. Clin. Neuropharmacol. 2015;38:221–226. doi: 10.1097/WNF.0000000000000107. - DOI - PubMed
1. Dressler D., Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev. Neurother. 2017;17:487–494. doi: 10.1080/14737175.2017.1262258. - DOI - PubMed
1. He X., Miao C.H., Li X.J., Wang Y.T., Liang Q., Zhang X.P., Wang Y.C. Biological characteristics and quality of botulinum toxin type A for injection. Chin. J. Biol. 2012;25:1488–1491. doi: 10.1124/pr.116.012658. (In Chinese) - DOI

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus. 1980;17:21–25. doi: 10.3928/0191-3913-19800101-06. - DOI - PubMed

[2] Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J. Pediatr. Ophthalmol. Strabismus. 1980;17:21–25. doi: 10.3928/0191-3913-19800101-06. - DOI - PubMed

[3] Dressler D. Botulinum toxin drugs: Brief history and outlook. J. Neural Transm. 2016;123:277–279. doi: 10.1007/s00702-015-1478-1. - DOI - PubMed

[4] Dressler D. Botulinum toxin drugs: Brief history and outlook. J. Neural Transm. 2016;123:277–279. doi: 10.1007/s00702-015-1478-1. - DOI - PubMed

[5] Barbosa P.M., Rodrigues G.R., de Oliveira D.S., de Souza C.P., Tumas V. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia. Clin. Neuropharmacol. 2015;38:221–226. doi: 10.1097/WNF.0000000000000107. - DOI - PubMed

[6] Barbosa P.M., Rodrigues G.R., de Oliveira D.S., de Souza C.P., Tumas V. Comparison Between Dysport and Prosigne in the Treatment of Cervical Dystonia. Clin. Neuropharmacol. 2015;38:221–226. doi: 10.1097/WNF.0000000000000107. - DOI - PubMed

[7] Dressler D., Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev. Neurother. 2017;17:487–494. doi: 10.1080/14737175.2017.1262258. - DOI - PubMed

[8] Dressler D., Bigalke H. Immunological aspects of botulinum toxin therapy. Expert Rev. Neurother. 2017;17:487–494. doi: 10.1080/14737175.2017.1262258. - DOI - PubMed

[9] He X., Miao C.H., Li X.J., Wang Y.T., Liang Q., Zhang X.P., Wang Y.C. Biological characteristics and quality of botulinum toxin type A for injection. Chin. J. Biol. 2012;25:1488–1491. doi: 10.1124/pr.116.012658. (In Chinese) - DOI

[10] He X., Miao C.H., Li X.J., Wang Y.T., Liang Q., Zhang X.P., Wang Y.C. Biological characteristics and quality of botulinum toxin type A for injection. Chin. J. Biol. 2012;25:1488–1491. doi: 10.1124/pr.116.012658. (In Chinese) - DOI

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review

Affiliations

Lantox-The Chinese Botulinum Toxin Drug-Complete English Bibliography and Comprehensive Formalised Literature Review

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical